



JAGSONPAL

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341-26498342 Phone : 0091-11-26498341-24

CIN: L74899DL1978PLC009181**JPL/SEC/RESU-NOT1****Date : February 13th, 2015**

The National Stock Exchange of India Limited
Kind Attn. Mr. Hari K. - Vice President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041

**SUB: UN-AUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31.12.2014
& AUDITOR'S REPORT ON FINANCIAL RESULTS. (LIMITED REVIEW)**

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith un-audited financial results for the quarter/year ended 31st December, 2014 and Auditor's Report on Financial Results..(Limited Review)

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**



R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl. : As above.



EST. 1983

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: J-210, Shantipur Jat, New Delhi - 110 049 (INDIA)

Fax: 0091-11-26498341, 26444106 Phone: 0091-11-26498341, 26444106

 CIN No.: L74899DL1978PLC000181
 Unaudited Financial Results for the Quarter / Half year ended 31.12.2014

Particulars	3 months ended 31.12.2014 Unaudited	3 months ended 30.09.2014 Unaudited	3 months ended 31.12.2013 Unaudited	9 Months ended 31.12.2014 Unaudited	9 Months ended 31.12.2013 Unaudited	Rs. in lacs 12 Months ended 31.03.2014 Audited
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	3242.86	3298.06	3770.16	8930.23	11257.01	14385.09
b Other Operating Income						
Total Income from operations (net)	3242.86	3298.06	3770.16	8930.23	11257.01	14385.09
2 Expenses						
a Cost of materials consumed	1561.32	1903.77	1467.69	4422.71	4414.50	5461.64
b Purchases of stock-in-trade	50.18	347.08	305.49	608.89	729.42	1294.90
c Changes in inventories of finished goods, work in progress and	-48.08	859.79	132.95	-443.02	553.24	-285.04
d Employee benefits expenses	744.79	754.6	913.54	2394.37	2761.41	3782.43
e Depreciation and amortisation expense	71.76	71.81	73.90	214.56	214.03	282.54
f Other expenses	742.01	813.35	660.98	2226.03	2001.53	3083.27
Total expenses	3127.98	3120.83	3544.54	9421.84	10774.13	13509.84
3 Profit from Operations before Other Income, Finance Cost and						
Exceptional items (1-2)	114.88	177.23	225.62	508.39	482.88	785.25
4 Other Income	0.41	2.03		5.55	0.00	6.07
5 Profit from ordinary activities before finance cost and	115.29	179.26	225.62	514.14	482.88	791.32
Exceptional items (3+4)						
6 Finance Cost	112.01	107.54	108.22	340.16	355.04	538.19
7 Profit from ordinary activities after finance cost but before	3.28	89.72	117.40	173.98	127.85	253.13
Exceptional items (5-6)						
8 Exceptional Items						
9 Profit/(+)/Loss(-) from Ordinary Activities before tax (7+8)	3.28	89.72	117.40	173.98	127.85	253.13
10 Tax expense	0.66	33.00	28.48	63.66	37.98	41.06
11 Net Profit/(loss) from Ordinary Activities after tax (9-10)	2.62	56.72	88.92	110.32	89.87	212.07
12 Extraordinary Items (net of tax expense Rs. in lacs)						
13 Net Profit/(+)/Loss(-) for the period (11-12)	2.62	56.72	88.92	110.32	89.87	212.07
14 Share of profit/(Loss) of associates						
15 Minority Interest						
16 Net Profit/(Loss) after taxes, minority interest and share of	2.62	56.72	88.92	110.32	89.87	212.07
17 Paid up Eq. Sh. Cap (Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet						
of pr. Accounting yr.						7298.31
19.1 Earnings Per Share (before extraordinary items)						
a Basic (Rs.)	0.01	0.14	0.34	0.42	0.34	0.81
b Diluted (Rs.)	0.01	0.14	0.34	0.42	0.34	0.81
19.2 Earnings Per Share (after extraordinary items)						
a Basic (Rs.)	0.01	0.14	0.34	0.42	0.34	0.81
b Diluted (Rs.)	0.01	0.14	0.34	0.42	0.34	0.81
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of shares	8076680	8076680	8062360	8076680	8062360	8062360
- Percentage of Shareholding	30.83%	30.83%	34.21%	30.83%	34.21%	34.21%
2 Promoter and promoter group shareholding						
A Pledged / encumbered						
- Number of shares						
- Percentage of shares (as a % of the total shareholding of						
Promoter and promoter group)						
- Percentage of shares (as a % of the total share capital of the						
Company)						
B Non - encumbered						
- Number of shares	18121320	19121320	17233640	18121320	17233640	17233640
- Percentage of shares (as a % of the total shareholding of	100%	100%	100%	100%	100%	100%
Promoter and promoter group)						
- Percentage of shares (as a % of the total share capital of the	69.17%	69.17%	65.79%	69.17%	65.79%	65.79%
Company)						
B INVESTOR COMPLAINTS						
Pending at the beginning of the quarter	0					
Received during the quarter	23					
Disposed of during the quarter	23					
Remaining unresolved at the end of the quarter	0					

Notes

- The Unaudited Financial Results for the Quarter ended 31.12.2014 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 13.02.2015.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.


 By Order of the Board
 For Jagsonpal Pharmaceuticals Limited

 Rajpal Singh Kochhar
 Managing Director
 DIN No 00050492

 Place: New Delhi
 Date: 13.02.2015

 Factory: 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953
 Factory: Plot No. 14, 15, 16, 55, 56, 57, Sector 5, 1F, Part Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DL1978PLC000181

P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre,

Babar Road, New Delhi - 110 001

Ph. (O) : 23413486

E-mail : sureshsethi62@yahoo.com


LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED**TO WHOM IT MAY CONCERN**

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 31.12.2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO.,
Chartered Accountants



SURESH SETHI
PARTNER

F.R. No. 000632 N

Membership no. 89318

Place : New Delhi
Date : 13.02.2015